Massachusetts General Hospital Archives - PeptideBlog

Massachusetts General Hospital

Massachusetts General Hospital

3 registered trials on this site, 0 active. This page lists the trials this organization is registered as lead sponsor of, for the compounds covered on PeptideBlog.net. It is a registry listing, not an assessment of the company or its products.

Compounds covered

Registered trials

TrialCompoundPhaseStatusSponsorEnrolledPrimary completionRegistry updated
AT1001 for the Treatment of Long COVID
NCT05747534
LarazotidePhase 2CompletedMassachusetts General Hospital107Jun 18, 2026Aug 18, 2026
AT1001 for the Treatment of COVID-19 Related MIS-C
NCT05022303
LarazotidePhase 2TerminatedMassachusetts General Hospital12May 15, 2024Jun 13, 2024
Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling
NCT01438073
Kisspeptin-10Phase 1CompletedMassachusetts General Hospital96Apr 2016Jul 11, 2022

Data: ClinicalTrials.gov, U.S. National Library of Medicine. See the full trial tracker.